# Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

> **NCT06821880** · — · RECRUITING · sponsor: **Medical University Innsbruck** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukaemia (CLL)
- Multiple Myeloma (MM)
- Secondary Immunodeficiency (SID)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06821880
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-03
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821880, "Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06821880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*